The prevalence of peripheral neuropathy severe enough to cause a loss of protective sensation in a population‐based sample of people with known and newly detected diabetes in Barbados: a cross‐sectional study

To determine the prevalence and potential risk factors for diabetic peripheral neuropathy with a loss of protective sensation in Barbados.

[1]  I. Hambleton,et al.  Prevalence and phenotype of diabetes and prediabetes using fasting glucose vs HbA1c in a Caribbean population , 2017, Journal of global health.

[2]  A. Paterson.  HbA1c for type 2 diabetes diagnosis in Africans and African Americans: Personalized medicine NOW! , 2017, PLoS medicine.

[3]  Benjamin A Lipsky,et al.  Prevention and management of foot problems in diabetes: A Summary Guidance for Daily Practice 2015, based on the IWGDF guidance documents. , 2017, Diabetes research and clinical practice.

[4]  I. Hambleton,et al.  Social distribution of diabetes, hypertension and related risk factors in Barbados: a cross-sectional study , 2015, BMJ Open.

[5]  Charles G. Taylor,et al.  The extensive inpatient burden of diabetes and diabetes-related foot disease in Barbados. , 2014, Clinical medicine.

[6]  G. Reiber,et al.  Peripheral Neuropathy Defined by Monofilament Insensitivity and Diabetes Status , 2013, Diabetes Care.

[7]  G. Booth,et al.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Methods. , 2013, Canadian journal of diabetes.

[8]  J. Albers,et al.  Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[9]  O. P. Adams,et al.  Are primary care practitioners in Barbados following diabetes guidelines? - a chart audit with comparison between public and private care sectors , 2011, BMC Research Notes.

[10]  A. Hamsten,et al.  The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. , 2011, Journal of diabetes and its complications.

[11]  Y. Bao,et al.  Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicentre survey in 12 city hospitals of China , 2010, Diabetes/metabolism research and reviews.

[12]  A. Panju,et al.  Does this patient with diabetes have large-fiber peripheral neuropathy? , 2010, JAMA.

[13]  S. Teelucksingh,et al.  Images in clinical medicine. Neuropathic ulceration. , 2010, The New England journal of medicine.

[14]  Michael J. Mueller,et al.  Comprehensive Foot Examination and Risk Assessment , 2008, Diabetes Care.

[15]  L. Lavery,et al.  Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. , 2005, Diabetes research and clinical practice.

[16]  D. Armstrong,et al.  Preventing foot ulcers in patients with diabetes. , 2005, JAMA.

[17]  N. Chaturvedi,et al.  Explanations for the high risk of diabetes-related amputation in a Caribbean population of black african descent and potential for prevention. , 2004, Diabetes care.

[18]  L. Bouter,et al.  Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. , 2003, Diabetes care.

[19]  T. Welborn,et al.  Foot complications in Type 2 diabetes: an Australian population‐based study , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[20]  J. Apelqvist,et al.  Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations , 2001, Diabetologia.

[21]  B. Zinman,et al.  Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic , 2001 .

[22]  J Booth,et al.  Differences in the performance of commercially available 10-g monofilaments. , 2000, Diabetes care.

[23]  E H Wagner,et al.  Incidence, outcomes, and cost of foot ulcers in patients with diabetes. , 1999, Diabetes care.

[24]  Amani S. Ibrahim,et al.  Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[25]  J. Shaw,et al.  Diabetic neuropathy in Mauritius: prevalence and risk factors. , 1998, Diabetes research and clinical practice.

[26]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[27]  C. McCabe,et al.  Evaluation of a diabetic foot screening and protection programme , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[28]  A. Adler,et al.  Risk Factors for Diabetic Peripheral Sensory Neuropathy: Results of the Seattle Prospective Diabetic Foot Study , 1997, Diabetes Care.

[29]  P. Sönksen,et al.  A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population , 1993, Diabetologia.

[30]  L. Wolff,et al.  Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements. , 1988, Journal of clinical periodontology.

[31]  Microvascular Complications and Foot Care : Standards of Medical Care in Diabetes d 2019 , 2018 .

[32]  A. Cheng.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. , 2013, Canadian journal of diabetes.

[33]  Richard Hellman,et al.  Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. , 2008, Physical therapy.